104 related articles for article (PubMed ID: 38759033)
1. Meta-analysis of the GALAD model for diagnosing primary hepatocellular carcinoma.
Lu JL; Yuan XY; Zhang JS; Li Y
Technol Health Care; 2024 May; ():. PubMed ID: 38759033
[TBL] [Abstract][Full Text] [Related]
2. The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis.
Guan MC; Zhang SY; Ding Q; Li N; Fu TT; Zhang GX; He QQ; Shen F; Yang T; Zhu H
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769597
[TBL] [Abstract][Full Text] [Related]
3. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
4. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.
Huang TS; Shyu YC; Turner R; Chen HY; Chen PJ
Syst Rev; 2013 Jun; 2():37. PubMed ID: 23738605
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.
Caviglia GP; Abate ML; Petrini E; Gaia S; Rizzetto M; Smedile A
Hepatol Res; 2016 Mar; 46(3):E130-5. PubMed ID: 26082262
[TBL] [Abstract][Full Text] [Related]
7. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
8. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
[TBL] [Abstract][Full Text] [Related]
9. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
10. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
[TBL] [Abstract][Full Text] [Related]
11. Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients.
Li L; Lu F; Chen P; Song H; Xu W; Guo J; Wang J; Zhou J; Kang X; Jin C; Cai Y; Feng Z; Gao H
Front Oncol; 2022; 12():1037742. PubMed ID: 36620588
[TBL] [Abstract][Full Text] [Related]
12. ASAP Score
Liu SY; Li C; Sun LY; Guan MC; Gu LH; Yin DX; Yao LQ; Liang L; Wang MD; Xing H; Zhu H; Pawlik TM; Lau WY; Shen F; Tong XM; Yang T
Front Oncol; 2022; 12():1018396. PubMed ID: 36263214
[TBL] [Abstract][Full Text] [Related]
13. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
14. Serologic Detection of Hepatocellular Carcinoma: Application of Machine Learning and Implications for Diagnostic Models.
Johnson PJ; Bhatti E; Toyoda H; He S
JCO Clin Cancer Inform; 2024 Mar; 8():e2300199. PubMed ID: 38513163
[TBL] [Abstract][Full Text] [Related]
15. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.
Sun LY; Wang NY; Diao YK; Yan CL; Fan ZP; Wei LH; Li HJ; Guan MC; Wang MD; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
Hepatobiliary Pancreat Dis Int; 2023 Dec; ():. PubMed ID: 38199909
[TBL] [Abstract][Full Text] [Related]
16. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
Yang JD; Addissie BD; Mara KC; Harmsen WS; Dai J; Zhang N; Wongjarupong N; Ali HM; Ali HA; Hassan FA; Lavu S; Cvinar JL; Giama NH; Moser CD; Miyabe K; Allotey LK; Algeciras-Schimnich A; Theobald JP; Ward MM; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Srivastava S; Rinaudo JA; Gores GJ; Feng Z; Marrero JA; Roberts LR
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):531-538. PubMed ID: 30464023
[TBL] [Abstract][Full Text] [Related]
17. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
[TBL] [Abstract][Full Text] [Related]
18. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
Chalasani NP; Porter K; Bhattacharya A; Book AJ; Neis BM; Xiong KM; Ramasubramanian TS; Edwards DK; Chen I; Johnson S; Roberts LR; Kisiel JB; Reddy KR; Singal AG; Olson MC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
[TBL] [Abstract][Full Text] [Related]
19. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
20. GALAD score and a proposal for GALADUS model for detecting hepatocellular carcinoma in Vietnamese patients with chronic liver disease.
Phuong PC; Khoa MT; Loi NT; Quynh VTT; Luan ND; Mai NTH; Dung NV; Hung NQ; Lieu DQ; Nam LV; Tra DT; Thai PV; Duc NM
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1111-1122. PubMed ID: 38375717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
